{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:59:10Z","timestamp":1786978750012,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":191,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032228994","type":"print"},{"value":"9783032229007","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/164_2025_780","type":"book-chapter","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:48:22Z","timestamp":1767026902000},"page":"59-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heparin: Over 100\u00a0Years of Anticoagulation"],"prefix":"10.1007","author":[{"given":"John","family":"Hogwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.thromres.2015.02.001","volume":"135","author":"W Ageno","year":"2015","unstructured":"Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M, Riete investigators (2015) Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 135:666\u2013672","journal-title":"Thromb Res"},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0035-1544228","volume":"41","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Prandoni P, Di Minno G, Cimminiello C, Scaglione F, Boracchi P, Molteni M, Polo Friz H, Di Minno MN, Marano G (2015) Thromboprophylaxis with low-molecular-weight heparins: an assessment of the methodological quality of studies. Semin Thromb Hemost 41:113\u2013132","journal-title":"Semin Thromb Hemost"},{"key":"780_CR3","doi-asserted-by":"publisher","unstructured":"Alban S (2012) Adverse effects of heparin. Handb Exp Pharmacol 207:211\u2013263. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_10. PMID: 22566227","DOI":"10.1007\/978-3-642-23056-1_10"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"107602962110522","DOI":"10.1177\/10760296211052293","volume":"27","author":"A Al-Hakim","year":"2021","unstructured":"Al-Hakim A (2021) General considerations for diversifying heparin drug products by improving the current heparin manufacturing process and reintroducing bovine sourced heparin to the US market. Clin Appl Thromb Hemost 27:10760296211052293","journal-title":"Clin Appl Thromb Hemost"},{"key":"780_CR5","first-page":"CD003747","volume":"5","author":"R Alikhan","year":"2014","unstructured":"Alikhan R, Bedenis R, Cohen AT (2014) Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 5:CD003747","journal-title":"Cochrane Database Syst Rev"},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","volume":"3","author":"DR Anderson","year":"2019","unstructured":"Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, Kahn SR, Rahman M, Rajasekhar A, Rogers FB, Smythe MA, Tikkinen KAO, Yates AJ, Baldeh T, Balduzzi S, Brozek JL, Ikobaltzeta IE, Johal H, Neumann I, Wiercioch W, Yepes-Nunez JJ, Schunemann HJ, Dahm P (2019) American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 3:3898\u20133944","journal-title":"Blood Adv"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0049-3848(76)90105-5","volume":"9","author":"LO Andersson","year":"1976","unstructured":"Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE (1976) Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res 9:575\u2013583","journal-title":"Thromb Res"},{"key":"780_CR8","first-page":"261","volume":"43","author":"JL Babin","year":"2017","unstructured":"Babin JL, Traylor KL, Witt DM (2017) Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost 43:261\u2013269","journal-title":"Semin Thromb Hemost"},{"key":"780_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/jth.13405","volume":"14","author":"T Bakchoul","year":"2016","unstructured":"Bakchoul T, Jouni R, Warkentin TE (2016) Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine\/heparin antibodies. J Thromb Haemost 14:1685\u20131695","journal-title":"J Thromb Haemost"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/bjh.19729","volume":"205","author":"P Baker","year":"2024","unstructured":"Baker P, Platton S, Arachchillage DJ, Kitchen S, Patel J, Riat R, Gomez K, Committee BSH (2024) Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology guideline. Br J Haematol 205:1302\u20131318","journal-title":"Br J Haematol"},{"key":"780_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","volume":"10","author":"I Baluwala","year":"2017","unstructured":"Baluwala I, Favaloro EJ, Pasalic L (2017) Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol 10:595\u2013605","journal-title":"Expert Rev Hematol"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood.V96.4.1618","volume":"96","author":"C Barnes","year":"2000","unstructured":"Barnes C, Deidun D, Hynes K, Monagle P (2000) Alopecia and dalteparin: a previously unreported association. Blood 96:1618\u20131619","journal-title":"Blood"},{"key":"780_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","volume":"1","author":"DW Barritt","year":"1960","unstructured":"Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309\u20131312","journal-title":"Lancet"},{"key":"780_CR14","doi-asserted-by":"publisher","unstructured":"Barrowcliffe TW (2012) History of heparin. Handb Exp Pharmacol 207:3\u201322. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_1. PMID: 22566218","DOI":"10.1007\/978-3-642-23056-1_1"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"e691S","DOI":"10.1378\/chest.11-2300","volume":"141","author":"SM Bates","year":"2012","unstructured":"Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e691S\u2013e736S","journal-title":"Chest"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3109\/0284186X.2014.934397","volume":"53","author":"I Ben-Aharon","year":"2014","unstructured":"Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A (2014) Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. Acta Oncol 53:1230\u20131237","journal-title":"Acta Oncol"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.thromres.2014.09.033","volume":"134","author":"M Berresheim","year":"2014","unstructured":"Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ (2014) A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing? Thromb Res 134:1234\u20131240","journal-title":"Thromb Res"},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/1076029616685430","volume":"23","author":"S Bertini","year":"2017","unstructured":"Bertini S, Fareed J, Madaschi L, Risi G, Torri G, Naggi A (2017a) Characterization of PF4-heparin complexes by photon correlation spectroscopy and zeta potential. Clin Appl Thromb Hemost 23:725. https:\/\/doi.org\/10.1177\/1076029616685430","journal-title":"Clin Appl Thromb Hemost"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/molecules22071214","volume":"22","author":"S Bertini","year":"2017","unstructured":"Bertini S, Risi G, Guerrini M, Carrick K, Szajek AY, Mulloy B (2017b) Molecular weights of bovine and porcine heparin samples: comparison of chromatographic methods and results of a collaborative survey. Molecules 22:1214","journal-title":"Molecules"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1055\/s-0040-1715460","volume":"120","author":"DMH Beurskens","year":"2020","unstructured":"Beurskens DMH, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperger CP, Nicolaes GAF (2020) The anticoagulant and nonanticoagulant properties of heparin. Thromb Haemost 120:1371\u20131383","journal-title":"Thromb Haemost"},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bjh.15091","volume":"180","author":"EP Bianchini","year":"2018","unstructured":"Bianchini EP, Sebestyen A, Abache T, Bourti Y, Fontayne A, Richard V, Tamion F, Plantier JL, Doguet F, Borgel D (2018) Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine. Br J Haematol 180:715\u2013720","journal-title":"Br J Haematol"},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1055\/s-0038-1660139","volume":"54","author":"G Bratt","year":"1985","unstructured":"Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D (1985) A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 54:813\u2013817","journal-title":"Thromb Haemost"},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0041-1736188","volume":"39","author":"B Brenner","year":"2021","unstructured":"Brenner B, Grandone E, Makatsariya A, Khizroeva J, Bitsadze V, Tretyakova M (2021) Approach to the evaluation and treatment of venous thromboembolism in pregnancy. Semin Reprod Med 39:186\u2013193","journal-title":"Semin Reprod Med"},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40620-018-00576-w","volume":"32","author":"SM Brunelli","year":"2019","unstructured":"Brunelli SM, Cohen DE, Marlowe G, Liu D, Njord L, Van Wyck D, Aronoff G (2019) Safety and efficacy of heparin during dialysis in the context of systemic anticoagulant and antiplatelet medications. J Nephrol 32:453\u2013460","journal-title":"J Nephrol"},{"key":"780_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehn358","volume":"30","author":"A Budaj","year":"2009","unstructured":"Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KA, Wallentin L, Peters RJ, Granger CB, Joyner CD, Yusuf S, Oasis Investigators (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30:655\u2013661","journal-title":"Eur Heart J"},{"key":"780_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0022-5223(19)41499-2","volume":"69","author":"BS Bull","year":"1975","unstructured":"Bull BS, Korpman RA, Huse WM, Briggs BD (1975) Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69:674\u2013684","journal-title":"J Thorac Cardiovasc Surg"},{"key":"780_CR27","first-page":"209","volume":"26","author":"JP Caen","year":"1984","unstructured":"Caen JP (1984) Heparin: a 70 year history from 1914 to 1984. Nouv Rev Fr Hematol (1978) 26:209\u2013210","journal-title":"Nouv Rev Fr Hematol (1978)"},{"key":"780_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/ndt\/15.7.1086","volume":"15","author":"JS Cameron","year":"2000","unstructured":"Cameron JS (2000) Practical haemodialysis began with cellophane and heparin: the crucial role of William Thalhimer (1884-1961). Nephrol Dial Transplant 15:1086\u20131091","journal-title":"Nephrol Dial Transplant"},{"key":"780_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","volume":"134","author":"M Carrier","year":"2014","unstructured":"Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134:1214\u20131219","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"780_CR30","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","volume":"212","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli G, Naggi A (2016) Old and new applications of non-anticoagulant heparin. Int J Cardiol 212(Suppl 1):S14\u2013S21","journal-title":"Int J Cardiol"},{"key":"780_CR31","doi-asserted-by":"publisher","unstructured":"Casu B, Lindahl U (2001) Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 57:159\u2013206. https:\/\/doi.org\/10.1016\/s0065-2318(01)57017-1. PMID: 11836942","DOI":"10.1016\/s0065-2318(01)57017-1"},{"key":"780_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S0140-6736(87)90510-1","volume":"1","author":"B Casu","year":"1987","unstructured":"Casu B, Naggi A, Oreste P, Torri G, Pangrazzj J, Maggi A, Abbadini M, Donati MB (1987) Bleeding associated with heparin contaminants. Lancet 1:1088","journal-title":"Lancet"},{"key":"780_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000175157","volume":"36","author":"B Casu","year":"2008","unstructured":"Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195\u2013203","journal-title":"Pathophysiol Haemost Thromb"},{"key":"780_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11239-014-1153-7","volume":"40","author":"NC Chan","year":"2014","unstructured":"Chan NC, Siegal D, Lauw MN, Ginsberg JS, Eikelboom JW, Guyatt GH, Hirsh J (2014) A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. J Thromb Thrombolysis 40:231","journal-title":"J Thromb Thrombolysis"},{"key":"780_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.arthro.2014.03.009","volume":"30","author":"C Chapelle","year":"2014","unstructured":"Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S, Group Meta-Embol (2014) Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy 30:987\u2013996","journal-title":"Arthroscopy"},{"key":"780_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0049-3848(80)90356-4","volume":"18","author":"J Choay","year":"1980","unstructured":"Choay J, Lormeau JC, Petitou M, Sinay P, Casu B, Oreste P, Torri G, Gatti G (1980) Anti-Xa active heparin oligosaccharides. Thromb Res 18:573\u2013578","journal-title":"Thromb Res"},{"key":"780_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1445-5994.1986.tb00023.x","volume":"16","author":"BH Chong","year":"1986","unstructured":"Chong BH, Castaldi PA (1986) Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust NZ J Med 16:715\u2013716","journal-title":"Aust NZ J Med"},{"key":"780_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-0037-1612949","volume":"87","author":"SD Chunilal","year":"2002","unstructured":"Chunilal SD, Young E, Johnston MA, Robertson C, Naguit I, Stevens P, Galashan D, Oskamp ML, Brennan B, Ginsberg JS (2002) The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 87:92\u201397","journal-title":"Thromb Haemost"},{"key":"780_CR39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM198703053161004","volume":"316","author":"DB Cines","year":"1987","unstructured":"Cines DB, Tomaski A, Tannenbaum S (1987) Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581\u2013589","journal-title":"N Engl J Med"},{"key":"780_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/sdi.12932","volume":"34","author":"SE Claudel","year":"2021","unstructured":"Claudel SE, Miles LA, Murea M (2021) Anticoagulation in hemodialysis: A narrative review. Semin Dial 34:103\u2013115","journal-title":"Semin Dial"},{"key":"780_CR41","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1185\/03007995.2012.688737","volume":"28","author":"AT Cohen","year":"2012","unstructured":"Cohen AT (2012) Long-term benefits of preventing venous thromboembolic events. Curr Med Res Opin 28:877\u2013889","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 2","key":"780_CR42","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0049-3848(10)70008-6","volume":"125","author":"AT Cohen","year":"2010","unstructured":"Cohen AT, Nandini B, Wills JO, Ota S (2010) VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. Thromb Res 125(Suppl 2):S21\u2013S29","journal-title":"Thromb Res"},{"key":"780_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.thromres.2013.09.040","volume":"133","author":"AT Cohen","year":"2014","unstructured":"Cohen AT, Dobromirski M, Gurwith MM (2014) Managing pulmonary embolism from presentation to extended treatment. Thromb Res 133:139\u2013148","journal-title":"Thromb Res"},{"key":"780_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.thromres.2021.11.012","volume":"218","author":"NT Connell","year":"2022","unstructured":"Connell NT, Sylvester KW (2022) To aPTT or not to aPTT: evaluating the optimal monitoring strategy for unfractionated heparin. Thromb Res 218:199\u2013200","journal-title":"Thromb Res"},{"key":"780_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/cc6810","volume":"12","author":"D Cook","year":"2008","unstructured":"Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Group Canadian Critical Care Trials (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 12:R32","journal-title":"Crit Care"},{"key":"780_CR46","first-page":"762","volume":"28","author":"AL Copley","year":"1943","unstructured":"Copley AL, Whitney DV III (1943) The standardization and assay of heparin by the toluidine blue and azure a reactions. J Lab Clin Med 28:762\u2013770","journal-title":"J Lab Clin Med"},{"key":"780_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0049-3848(98)00063-2","volume":"90","author":"E Coyne","year":"1998","unstructured":"Coyne E, Messmore HL, Walenga JM, Fareed J, Wehrmacher WH (1998) Ethylenediaminetetraacetic acid (EDTA) in heparin. Thromb Res 90:245\u2013246","journal-title":"Thromb Res"},{"key":"780_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1525-139X.2010.00770.x","volume":"23","author":"RE Cronin","year":"2010","unstructured":"Cronin RE, Reilly RF (2010) Unfractionated heparin for hemodialysis: still the best option. Semin Dial 23:510\u2013515","journal-title":"Semin Dial"},{"key":"780_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1055\/s-0028-1092877","volume":"34","author":"MA Crowther","year":"2008","unstructured":"Crowther MA, Cook DJ (2008) Preventing venous thromboembolism in critically ill patients. Semin Thromb Hemost 34:469\u2013474","journal-title":"Semin Thromb Hemost"},{"key":"780_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0002-9378(89)90096-3","volume":"160","author":"K de Boer","year":"1989","unstructured":"de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE (1989) Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 160:95\u2013100","journal-title":"Am J Obstet Gynecol"},{"key":"780_CR51","first-page":"CD008500","volume":"8","author":"M Di Nisio","year":"2014","unstructured":"Di Nisio M, Porreca E, Otten HM, Rutjes AW (2014) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 8:CD008500","journal-title":"Cochrane Database Syst Rev"},{"key":"780_CR52","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1055\/s-0039-1696658","volume":"3","author":"JD Dias","year":"2019","unstructured":"Dias JD, Lopez-Espina CG, Panigada M, Dalton HJ, Hartmann J, Achneck HE (2019) Cartridge-based thromboelastography can be used to monitor and quantify the activity of unfractionated and low-molecular-weight heparins. TH Open 3:e295\u2013e305","journal-title":"TH Open"},{"key":"780_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10517-019-04509-w","volume":"167","author":"NN Drozd","year":"2019","unstructured":"Drozd NN, Logvinova YS, Shagdarova BT, Il'ina AV, Varlamov VP (2019) Analysis of the action of quaternized chitosans with different molecular weight on anticoagulant activity of heparins in vitro. Bull Exp Biol Med 167:279\u2013283","journal-title":"Bull Exp Biol Med"},{"key":"780_CR54","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.109.872630","volume":"120","author":"JW Eikelboom","year":"2009","unstructured":"Eikelboom JW, Quinlan DJ, O'Donnell M (2009) Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 120:2006\u20132011","journal-title":"Circulation"},{"key":"780_CR55","doi-asserted-by":"publisher","first-page":"S759","DOI":"10.1016\/j.ajog.2022.10.013","volume":"230","author":"G Ekman-Ordeberg","year":"2024","unstructured":"Ekman-Ordeberg G, Hellgren-Wangdahl M, Jeppson A, Rahkonen L, Blomberg M, Pettersson K, Bejlum C, Engberg M, Ludvigsen M, Uotila J, Tihtonen K, Hallberg G, Jonsson M (2024) Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies. Am J Obstet Gynecol 230:S759\u2013SS68","journal-title":"Am J Obstet Gynecol"},{"key":"780_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4137\/CMO.S18991","volume":"8","author":"G Elyamany","year":"2014","unstructured":"Elyamany G, Alzahrani AM, Bukhary E (2014) Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 8:129\u2013137","journal-title":"Clin Med Insights Oncol"},{"key":"780_CR57","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1538-7836.2008.02984.x","volume":"6","author":"HB Ettema","year":"2008","unstructured":"Ettema HB, Kollen BJ, Verheyen CC, Buller HR (2008) Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost 6:1093\u20131098","journal-title":"J Thromb Haemost"},{"key":"780_CR58","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdi165","volume":"16","author":"A Falanga","year":"2005","unstructured":"Falanga A, Zacharski L (2005) Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16:696\u2013701","journal-title":"Ann Oncol"},{"key":"780_CR59","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404","volume":"141","author":"Y Falck-Ytter","year":"2012","unstructured":"Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr, Physicians American College of Chest (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e278S\u2013325S","journal-title":"Chest"},{"key":"780_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1067\/mtc.2002.121761","volume":"124","author":"VA Ferraris","year":"2002","unstructured":"Ferraris VA (2002) Heroes and evidence. J Thorac Cardiovasc Surg 124:11\u201313","journal-title":"J Thorac Cardiovasc Surg"},{"key":"780_CR61","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0038-1651102","volume":"57","author":"F Forestier","year":"1987","unstructured":"Forestier F, Daffos F, Rainaut M, Toulemonde F (1987) Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 57:234","journal-title":"Thromb Haemost"},{"key":"780_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/07853890.2015.1004361","volume":"47","author":"M Franchini","year":"2015","unstructured":"Franchini M, Mannucci PM (2015) Low-molecular-weight heparins and cancer: focus on antitumoral effect. Ann Med 47:116\u2013121","journal-title":"Ann Med"},{"key":"780_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-013-0889-9","volume":"35","author":"CW Francis","year":"2013","unstructured":"Francis CW (2013) Prevention of VTE in patients having major orthopedic surgery. J Thromb Thrombolysis 35:359\u2013367","journal-title":"J Thromb Thrombolysis"},{"key":"780_CR64","first-page":"347","volume-title":"Handbook of experimental pharmacology","author":"JT Gallagher","year":"2012","unstructured":"Gallagher JT (2012) Heparan sulphate: a heparin in miniature. In: Handbook of experimental pharmacology, pp 347\u2013360"},{"key":"780_CR65","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM, Physicians American College of Chest (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S\u201343S","journal-title":"Chest"},{"key":"780_CR66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000169116","volume":"17","author":"CW Gottschalk","year":"1997","unstructured":"Gottschalk CW, Fellner SK (1997) History of the science of dialysis. Am J Nephrol 17:289\u2013298","journal-title":"Am J Nephrol"},{"key":"780_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1076029607304722","volume":"15","author":"J Gozdzikiewicz","year":"2009","unstructured":"Gozdzikiewicz J, Borawski J, Mysliwiec M (2009) Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost 15:92\u201397","journal-title":"Clin Appl Thromb Hemost"},{"key":"780_CR68","volume-title":"An international collaborative study to value assign the 6th [sixth] international standard for unfractionated heparin and the US pharmacopeial heparin reference standard for assay Lot F","author":"E Gray","year":"2009","unstructured":"Gray E, Hogwood J, Rigsby P, Mulloy B, Szajek A, Ambrose M, Jameison F, Hauck W, Morris T (2009) An international collaborative study to value assign the 6th [sixth] international standard for unfractionated heparin and the US pharmacopeial heparin reference standard for assay Lot F. World Health Organisation"},{"key":"780_CR69","doi-asserted-by":"publisher","unstructured":"Gray E, Hogwood J, Mulloy B (2012) The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol 207:43\u201361. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_3. PMID: 22566220","DOI":"10.1007\/978-3-642-23056-1_3"},{"key":"780_CR70","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","volume":"106","author":"IA Greer","year":"2005","unstructured":"Greer IA, Nelson-Piercy C (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106:401\u2013407","journal-title":"Blood"},{"key":"780_CR71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bjh.13159","volume":"168","author":"B Guimicheva","year":"2015","unstructured":"Guimicheva B, Czuprynska J, Arya R (2015) The prevention of pregnancy-related venous thromboembolism. Br J Haematol 168:163\u2013174","journal-title":"Br J Haematol"},{"key":"780_CR72","doi-asserted-by":"publisher","first-page":"913","DOI":"10.21470\/1678-9741-2019-0387","volume":"35","author":"MO Hanedan","year":"2020","unstructured":"Hanedan MO, Yuruk MA, Arslan AK, Kilic A, Sayar U, Mataraci I (2020) Heparin-coated vs. non-coated cardiopulmonary bypass circuits: comparing immediate results with different target activated clotting time. Braz J Cardiovasc Surg 35:913\u2013917","journal-title":"Braz J Cardiovasc Surg"},{"key":"780_CR73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2014.05.056","volume":"193","author":"H He","year":"2014","unstructured":"He H, Ye J, Liu E, Liang Q, Liu Q, Yang VC (2014) Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide. J Control Release 193:63\u201373","journal-title":"J Control Release"},{"key":"780_CR74","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/jth.13555","volume":"14","author":"HC Hemker","year":"2016","unstructured":"Hemker HC (2016) A century of heparin: past, present and future. J Thromb Haemost 14:2329\u20132338","journal-title":"J Thromb Haemost"},{"key":"780_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1089253214530045","volume":"18","author":"EA Hessel 2nd","year":"2014","unstructured":"Hessel EA 2nd (2014) A brief history of cardiopulmonary bypass. Semin Cardiothorac Vasc Anesth 18:87\u2013100","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"780_CR76","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S\u201394S","journal-title":"Chest"},{"key":"780_CR77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/ph10030059","volume":"10","author":"J Hogwood","year":"2017","unstructured":"Hogwood J, Mulloy B, Gray E (2017) Precipitation and neutralization of heparin from different sources by protamine sulfate. Pharmaceuticals (Basel) 10:59","journal-title":"Pharmaceuticals (Basel)"},{"key":"780_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","volume":"75","author":"J Hogwood","year":"2023","unstructured":"Hogwood J, Mulloy B, Lever R, Gray E, Page CP (2023) Pharmacology of heparin and related drugs: an update. Pharmacol Rev 75:328\u2013379","journal-title":"Pharmacol Rev"},{"key":"780_CR79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1160\/TH03-11-0719","volume":"91","author":"M Hoke","year":"2004","unstructured":"Hoke M, Kyrle PA, Philipp K, Pabinger I, Kaider A, Schonauer V, Quehenberger P, Eichinger S (2004) Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin. Thromb Haemost 91:935\u2013940","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"780_CR80","first-page":"30","volume":"16","author":"HA Holm","year":"1986","unstructured":"Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F et al (1986) Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 16(Suppl 2):30\u201337","journal-title":"Haemostasis"},{"key":"780_CR81","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0196-0644(99)70104-6","volume":"34","author":"HC Hovanessian","year":"1999","unstructured":"Hovanessian HC (1999) New-generation anticoagulants: the low molecular weight heparins. Ann Emerg Med 34:768\u2013779","journal-title":"Ann Emerg Med"},{"key":"780_CR82","first-page":"328","volume":"47","author":"WH Howell","year":"1918","unstructured":"Howell WH, Holt E (1918) Two new factors in blood coagulation \u2013 heparin and pro-antithrombin. Am J Phys 47:328\u2013341","journal-title":"Am J Phys"},{"key":"780_CR83","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1016\/S0021-9258(18)91066-5","volume":"259","author":"M Hoylaerts","year":"1984","unstructured":"Hoylaerts M, Owen WG, Collen D (1984) Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. J Biol Chem 259:5670\u20135677","journal-title":"J Biol Chem"},{"key":"780_CR84","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJM199204093261502","volume":"326","author":"RD Hull","year":"1992","unstructured":"Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR et al (1992) Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975\u2013982","journal-title":"N Engl J Med"},{"key":"780_CR85","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fmed.2018.00360","volume":"5","author":"W Jeske","year":"2018","unstructured":"Jeske W, Kouta A, Farooqui A, Siddiqui F, Rangnekar V, Niverthi M, Laddu R, Hoppensteadt D, Iqbal O, Walenga J, Fareed J (2018) Bovine mucosal heparins are comparable to porcine mucosal heparin at USP potency adjusted levels. Front Med (Lausanne) 5:360","journal-title":"Front Med (Lausanne)"},{"key":"780_CR86","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0008-6215(00)84041-0","volume":"51","author":"EA Johnson","year":"1976","unstructured":"Johnson EA, Mulloy B (1976) The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 51:119\u2013127","journal-title":"Carbohydr Res"},{"key":"780_CR87","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1055\/s-0038-1648001","volume":"35","author":"EA Johnson","year":"1976","unstructured":"Johnson EA, Kirkwood TB, Stirling Y, Perez-Requejo JL, Ingram GI, Bangham DR, Brozovic M (1976) Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 35:586\u2013591","journal-title":"Thromb Haemost"},{"key":"780_CR88","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1749-6632.1964.tb41069.x","volume":"115","author":"JE Jorpes","year":"1964","unstructured":"Jorpes JE (1964) The early history of heparin. Ann N Y Acad Sci 115:392\u2013398","journal-title":"Ann N Y Acad Sci"},{"key":"780_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/jpet.119.262931","volume":"373","author":"B Kalaska","year":"2020","unstructured":"Kalaska B, Miklosz J, Kami\u0144ski K, Swieton J, Jakimczuk A, Yusa SI, Pawlak D, Nowakowska M, Szczubia\u0142ka K, Mogielnicki A (2020) Heparin-binding copolymer as a complete antidote for low-molecular-weight heparins in rats. J Pharmacol Exp Ther 373:51\u201361","journal-title":"J Pharmacol Exp Ther"},{"key":"780_CR90","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13346-017-0413-4","volume":"8","author":"MT Kalathottukaren","year":"2018","unstructured":"Kalathottukaren MT, Haynes CA, Kizhakkedathu JN (2018) Approaches to prevent bleeding associated with anticoagulants: current status and recent developments. Drug Deliv Transl Res 8:928\u2013944","journal-title":"Drug Deliv Transl Res"},{"issue":"Suppl 2","key":"780_CR91","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","volume":"133","author":"PW Kamphuisen","year":"2014","unstructured":"Kamphuisen PW, Beyer-Westendorf J (2014) Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res 133(Suppl 2):S49\u2013S55","journal-title":"Thromb Res"},{"key":"780_CR92","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","volume":"123","author":"C Kearon","year":"2014","unstructured":"Kearon C, Akl EA (2014) Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 123:1794\u20131801","journal-title":"Blood"},{"key":"780_CR93","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, Physicians American College of Chest (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S\u201394S","journal-title":"Chest"},{"key":"780_CR94","first-page":"2","volume":"39","author":"DA Keire","year":"2015","unstructured":"Keire DA, Mulloy B, Chase C, Al-Hakim A, Cairatti D, Gray E, Hogwood J, Morris T, Mourao P, Soares M, Szajek A (2015) Diversifying the global heparin supply chain reintroduction of bovine heparin in the United States. Pharm Technol 39:2\u20138","journal-title":"Pharm Technol"},{"key":"780_CR95","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","volume":"72","author":"JG Kelton","year":"1988","unstructured":"Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG (1988) Heparin-induced thrombocytopenia: laboratory studies. Blood 72:925\u2013930","journal-title":"Blood"},{"key":"780_CR96","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1182\/blood-2018-03-834598","volume":"132","author":"S Khandelwal","year":"2018","unstructured":"Khandelwal S, Ravi J, Rauova L, Johnson A, Lee GM, Gilner JB, Gunti S, Notkins AL, Kuchibhatla M, Frank M, Poncz M, Cines DB, Arepally GM (2018) Polyreactive IgM initiates complement activation by PF4\/heparin complexes through the classical pathway. Blood 132:2431\u20132440","journal-title":"Blood"},{"key":"780_CR97","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1160\/TH06-10-0606","volume":"97","author":"A Kher","year":"2007","unstructured":"Kher A, Bauersachs R, Nielsen JD (2007) The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 97:505\u2013513","journal-title":"Thromb Haemost"},{"key":"780_CR98","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490\u2013493","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"780_CR99","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S0049-3848(12)70009-9","volume":"129","author":"AA Khorana","year":"2012","unstructured":"Khorana AA (2012) Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res 129(Suppl 1):S10\u2013S15","journal-title":"Thromb Res"},{"issue":"Suppl 2","key":"780_CR100","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","volume":"133","author":"AA Khorana","year":"2014","unstructured":"Khorana AA, McCrae KR (2014) Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 133(Suppl 2):S35\u2013S38","journal-title":"Thromb Res"},{"key":"780_CR101","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0002-9149(03)00972-X","volume":"92","author":"TD Kinnaird","year":"2003","unstructured":"Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92:930\u2013935","journal-title":"Am J Cardiol"},{"key":"780_CR102","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","volume":"358","author":"TK Kishimoto","year":"2008","unstructured":"Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457\u20132467","journal-title":"N Engl J Med"},{"key":"780_CR103","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1093\/eurheartj\/ehu243","volume":"35","author":"SV Konstantinides","year":"2014","unstructured":"Konstantinides SV (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3145\u20133146","journal-title":"Eur Heart J"},{"key":"780_CR104","doi-asserted-by":"publisher","first-page":"107602962110055","DOI":"10.1177\/10760296211005544","volume":"27","author":"A Kouta","year":"2021","unstructured":"Kouta A, Jeske W, Cera L, Farshid A, Duff R, Hoppensteadt D, Fareed J (2021) Protamine sulfate neutralization profile of various dosages of bovine, ovine and porcine UFHs and their depolymerized derivatives in non-human primates. Clin Appl Thromb Hemost 27:10760296211005544","journal-title":"Clin Appl Thromb Hemost"},{"issue":"Suppl 2","key":"780_CR105","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0049-3848(14)50003-5","volume":"133","author":"PA Kyrle","year":"2014","unstructured":"Kyrle PA (2014) Predicting recurrent venous thromboembolism in cancer: is it possible? Thromb Res 133(Suppl 2):S17\u2013S22","journal-title":"Thromb Res"},{"key":"780_CR106","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","volume":"69","author":"LH Lam","year":"1976","unstructured":"Lam LH, Silbert JE, Rosenberg RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570\u2013577","journal-title":"Biochem Biophys Res Commun"},{"key":"780_CR107","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/MCP.0b013e3283061191","volume":"14","author":"G Le Templier","year":"2008","unstructured":"Le Templier G, Rodger MA (2008) Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 14:403\u2013407","journal-title":"Curr Opin Pulm Med"},{"key":"780_CR108","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archinte.158.8.873","volume":"158","author":"JR Leclerc","year":"1998","unstructured":"Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS (1998) The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 158:873\u2013878","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"780_CR109","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0049-3848(10)70004-9","volume":"125","author":"AY Lee","year":"2010","unstructured":"Lee AY (2010) The roles of anticoagulants in patients with cancer. Thromb Res 125(Suppl 2):S8\u2013S11","journal-title":"Thromb Res"},{"key":"780_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Investigators Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153","journal-title":"N Engl J Med"},{"key":"780_CR111","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40620-019-00592-4","volume":"32","author":"KC Leung","year":"2019","unstructured":"Leung KC, MacRae JM (2019) Anticoagulation in CKD and ESRD. J Nephrol 32:719\u2013731","journal-title":"J Nephrol"},{"key":"780_CR112","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","volume":"2","author":"W Lim","year":"2018","unstructured":"Lim W, Le Gal G, Bates SM, Righini M, Haramati LB, Lang E, Kline JA, Chasteen S, Snyder M, Patel P, Bhatt M, Patel P, Braun C, Begum H, Wiercioch W, Schunemann HJ, Mustafa RA (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2:3226\u20133256","journal-title":"Blood Adv"},{"key":"780_CR113","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev.bi.47.070178.002125","volume":"47","author":"U Lindahl","year":"1978","unstructured":"Lindahl U, Hook M (1978) Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 47:385\u2013417","journal-title":"Annu Rev Biochem"},{"key":"780_CR114","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1073\/pnas.76.7.3198","volume":"76","author":"U Lindahl","year":"1979","unstructured":"Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson LA, Linker A (1979) Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 76:3198\u20133202","journal-title":"Proc Natl Acad Sci USA"},{"key":"780_CR115","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1039\/b819896a","volume":"26","author":"H Liu","year":"2009","unstructured":"Liu H, Zhang Z, Linhardt RJ (2009) Lessons learned from the contamination of heparin. Nat Prod Rep 26:313\u2013321","journal-title":"Nat Prod Rep"},{"key":"780_CR116","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00402-014-1939-2","volume":"134","author":"F Liu","year":"2014","unstructured":"Liu F, Chu X, Huang J, Tian K, Hua J, Tong P (2014) Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. Arch Orthop Trauma Surg 134:679\u2013683","journal-title":"Arch Orthop Trauma Surg"},{"key":"780_CR117","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.thromres.2012.01.017","volume":"129","author":"F Lussana","year":"2012","unstructured":"Lussana F, Coppens M, Cattaneo M, Middeldorp S (2012) Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res 129:673\u2013680","journal-title":"Thromb Res"},{"key":"780_CR118","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5:927\u2013974","journal-title":"Blood Adv"},{"key":"780_CR119","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1378\/chest.125.5.1616","volume":"125","author":"C Macie","year":"2004","unstructured":"Macie C, Forbes L, Foster GA, Douketis JD (2004) Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 125:1616\u20131621","journal-title":"Chest"},{"key":"780_CR120","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1060028020943160","volume":"55","author":"JN Maneno","year":"2021","unstructured":"Maneno JN, Ness GL (2021) Andexanet alfa, the possible alternative to protamine for reversal of unfractionated heparin. Ann Pharmacother 55:261\u2013264","journal-title":"Ann Pharmacother"},{"key":"780_CR121","doi-asserted-by":"publisher","first-page":"II24-34","DOI":"10.1002\/clc.20238","volume":"30","author":"SV Manoukian","year":"2007","unstructured":"Manoukian SV, Voeltz MD, Eikelboom J (2007) Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 30:II24-34","journal-title":"Clin Cardiol"},{"key":"780_CR122","first-page":"253","volume":"43","author":"RA Marlar","year":"2017","unstructured":"Marlar RA, Clement B, Gausman J (2017) Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 43:253\u2013260","journal-title":"Semin Thromb Hemost"},{"key":"780_CR123","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3810\/pgm.2014.11.2830","volume":"126","author":"AL Marshall","year":"2014","unstructured":"Marshall AL (2014) Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy. Postgrad Med 126:25\u201334","journal-title":"Postgrad Med"},{"key":"780_CR124","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","volume":"106","author":"N Martel","year":"2005","unstructured":"Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710\u20132715","journal-title":"Blood"},{"key":"780_CR125","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1177\/02676591231215282","volume":"39","author":"L Mathieu","year":"2024","unstructured":"Mathieu L, Beurton A, Rougier N, Flambard M, Germain C, Pernot M, Ouattara A (2024) Heparin consumption and inflammatory response according to the coating of cardiopulmonary bypass circuits in cardiac surgery: A retrospective analysis. Perfusion 39:1531\u20131537","journal-title":"Perfusion"},{"key":"780_CR126","first-page":"250","volume":"41","author":"J McLean","year":"1916","unstructured":"McLean J (1916) The thromboplastic action of cephalin. Am J Phys 41:250\u2013257","journal-title":"Am J Phys"},{"key":"780_CR127","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccc.2011.07.001","volume":"27","author":"AG McLeod","year":"2011","unstructured":"McLeod AG, Geerts W (2011) Venous thromboembolism prophylaxis in critically ill patients. Crit Care Clin 27:765\u201380, v","journal-title":"Crit Care Clin"},{"key":"780_CR128","first-page":"262","volume":"9","author":"HL McRae","year":"2021","unstructured":"McRae HL, Militello L, Refaai MA (2021) Updates in anticoagulation therapy monitoring. Biomedicine 9:262","journal-title":"Biomedicine"},{"key":"780_CR129","doi-asserted-by":"publisher","first-page":"0589","DOI":"10.1098\/rsif.2015.0589","volume":"12","author":"MC Meneghetti","year":"2015","unstructured":"Meneghetti MC, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA, Lima MA (2015) Heparan sulfate and heparin interactions with proteins. J R Soc Interface 12:0589","journal-title":"J R Soc Interface"},{"key":"780_CR130","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1046\/j.0007-1323.2001.01800.x","volume":"88","author":"P Mismetti","year":"2001","unstructured":"Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913\u2013930","journal-title":"Br J Surg"},{"key":"780_CR131","doi-asserted-by":"publisher","unstructured":"Mulloy B (2012) Structure and physicochemical characterisation of heparin. Handb Exp Pharmacol 207:77\u201398. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_5. PMID: 22566222","DOI":"10.1007\/978-3-642-23056-1_5"},{"key":"780_CR132","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coph.2019.03.009","volume":"46","author":"B Mulloy","year":"2019","unstructured":"Mulloy B (2019) The non-anticoagulant promise of heparin and its mimetics. Curr Opin Pharmacol 46:50\u201354","journal-title":"Curr Opin Pharmacol"},{"key":"780_CR133","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0959-440X(00)00257-8","volume":"11","author":"B Mulloy","year":"2001","unstructured":"Mulloy B, Linhardt RJ (2001) Order out of complexity--protein structures that interact with heparin. Curr Opin Struct Biol 11:623\u2013628","journal-title":"Curr Opin Struct Biol"},{"key":"780_CR134","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1055\/s-0037-1614170","volume":"84","author":"B Mulloy","year":"2000","unstructured":"Mulloy B, Gray E, Barrowcliffe TW (2000) Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 84:1052\u20131056","journal-title":"Thromb Haemost"},{"key":"780_CR135","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","volume":"68","author":"B Mulloy","year":"2016","unstructured":"Mulloy B, Hogwood J, Gray E, Lever R, Page CP (2016) Pharmacology of heparin and related drugs. Pharmacol Rev 68:76\u2013141","journal-title":"Pharmacol Rev"},{"key":"780_CR136","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2017.05.012","volume":"155","author":"V Muralidharan-Chari","year":"2017","unstructured":"Muralidharan-Chari V, Kim J, Mousa SA (2017) Reversal of anticoagulant activity of heparin and low molecular weight heparins by poly-l-lysine: a comparative 'in vitro' study versus protamine sulfate. Thromb Res 155:128\u2013130","journal-title":"Thromb Res"},{"key":"780_CR137","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2174\/1381612043452758","volume":"10","author":"HB Nader","year":"2004","unstructured":"Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP (2004) Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des 10:951\u2013966","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"780_CR138","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1016\/S0049-3848(12)70029-4","volume":"129","author":"S Noble","year":"2012","unstructured":"Noble S (2012) Low-molecular-weight heparin and survival in lung cancer. Thromb Res 129(Suppl 1):S114\u2013S118","journal-title":"Thromb Res"},{"key":"780_CR139","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.athoracsur.2019.03.104","volume":"108","author":"CS Ong","year":"2019","unstructured":"Ong CS, Marcum JA, Zehr KJ, Cameron DE (2019) A century of heparin. Ann Thorac Surg 108:955\u2013958","journal-title":"Ann Thorac Surg"},{"key":"780_CR140","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, Florez I D, Izcovich A, Nieuwlaat R, Ross S, Schunemann H J, Wiercioch W, Zhang Y, Zhang Y (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4:4693\u20134738","journal-title":"Blood Adv"},{"key":"780_CR141","doi-asserted-by":"publisher","unstructured":"Pai M, Crowther MA (2012) Neutralization of heparin activity. Handb Exp Pharmacol 207:265\u2013277. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_11. PMID: 22566228","DOI":"10.1007\/978-3-642-23056-1_11"},{"key":"780_CR142","first-page":"65","volume":"27","author":"AJ Palmer","year":"1997","unstructured":"Palmer AJ, Schramm W, Kirchhof B, Bergemann R (1997) Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 27:65\u201374","journal-title":"Haemostasis"},{"key":"780_CR143","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11239-015-1261-z","volume":"41","author":"AF Paschoa","year":"2016","unstructured":"Paschoa AF (2016) Heparin: 100 years of pleiotropic effects. J Thromb Thrombolysis 41:636\u2013643","journal-title":"J Thromb Thrombolysis"},{"key":"780_CR144","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1002\/anie.200300640","volume":"43","author":"M Petitou","year":"2004","unstructured":"Petitou M, van Boeckel CA (2004) A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed Engl 43:3118\u20133133","journal-title":"Angew Chem Int Ed Engl"},{"key":"780_CR145","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0300-9084(03)00078-6","volume":"85","author":"M Petitou","year":"2003","unstructured":"Petitou M, Casu B, Lindahl U (2003) 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 85:83\u201389","journal-title":"Biochimie"},{"key":"780_CR146","unstructured":"PharmEur_07\/2023:0828. Heparins, Low Molecular Mass, European Pharmacopoeia"},{"key":"780_CR147","unstructured":"PharmEur_07\/2024:0333. Heparin sodium, European Pharmacopoeia, 07\/2024:0333"},{"key":"780_CR148","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1182\/blood.V97.10.3300","volume":"97","author":"C Pouplard","year":"2001","unstructured":"Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97:3300\u20133302","journal-title":"Blood"},{"key":"780_CR149","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","volume":"339","author":"P Prandoni","year":"1992","unstructured":"Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441\u2013445","journal-title":"Lancet"},{"key":"780_CR150","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-0035-1544161","volume":"41","author":"P Prandoni","year":"2015","unstructured":"Prandoni P, Lensing AW, Prins MH, Pesavento R, Piccioli A, Sartori MT, Tormene D, Milan M, Vedovetto V, Noventa F, Villalta S, Harenberg J (2015) The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 41:133\u2013140","journal-title":"Semin Thromb Hemost"},{"key":"780_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111561","volume":"139","author":"M Qiu","year":"2021","unstructured":"Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J (2021) Pharmacological and clinical application of heparin progress: an essential drug for modern medicine. Biomed Pharmacother 139:111561","journal-title":"Biomed Pharmacother"},{"key":"780_CR152","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7326\/0003-4819-140-3-200402030-00008","volume":"140","author":"DJ Quinlan","year":"2004","unstructured":"Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 140:175\u2013183","journal-title":"Ann Intern Med"},{"key":"780_CR153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","volume":"105","author":"L Rauova","year":"2005","unstructured":"Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131\u2013138","journal-title":"Blood"},{"key":"780_CR154","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/ATVBAHA.111.242818","volume":"32","author":"PH Reitsma","year":"2012","unstructured":"Reitsma PH, Versteeg HH, Middeldorp S (2012) Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32:563\u2013568","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"780_CR155","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1538-7836.2010.03848.x","volume":"8","author":"H Riess","year":"2010","unstructured":"Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Rossol S, Pfeiffer B, Schellong SM (2010) A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY study. J Thromb Haemost 8:1209\u20131215","journal-title":"J Thromb Haemost"},{"key":"780_CR156","first-page":"CD010837","volume":"3","author":"L Robertson","year":"2015","unstructured":"Robertson L, Yeoh SE, Stansby G, Agarwal R (2015) Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE. Cochrane Database Syst Rev 3:CD010837","journal-title":"Cochrane Database Syst Rev"},{"key":"780_CR157","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","volume":"100","author":"N Ruiz-Gimenez","year":"2008","unstructured":"Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, Monreal M, Riete Investigators (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26\u201331","journal-title":"Thromb Haemost"},{"key":"780_CR158","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1016\/S0272-6386(03)00211-7","volume":"41","author":"E Sarris","year":"2003","unstructured":"Sarris E, Tsele E, Bagiatoudi G, Salpigidis K, Stavrianaki D, Kaklamanis L, Siakotos M (2003) Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis 41:E15","journal-title":"Am J Kidney Dis"},{"key":"780_CR159","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1503\/cmaj.081729","volume":"181","author":"M Schindewolf","year":"2009","unstructured":"Schindewolf M, Schwaner S, Wolter M, Kroll H, Recke A, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ (2009) Incidence and causes of heparin-induced skin lesions. CMAJ 181:477\u2013481","journal-title":"CMAJ"},{"key":"780_CR160","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","volume":"399","author":"M Schroeder","year":"2011","unstructured":"Schroeder M, Hogwood J, Gray E, Mulloy B, Hackett AM, Johansen KB (2011) Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal Bioanal Chem 399:763\u2013771","journal-title":"Anal Bioanal Chem"},{"key":"780_CR161","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:257S\u2013298S","journal-title":"Chest"},{"key":"780_CR162","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nchem.1701","volume":"5","author":"Z Shriver","year":"2013","unstructured":"Shriver Z, Sasisekharan R (2013) Heparin sensing: blue-chip binding. Nat Chem 5:644\u2013646","journal-title":"Nat Chem"},{"key":"780_CR163","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1051\/ject\/200941073","volume":"41","author":"AN Sievert","year":"2009","unstructured":"Sievert AN, Shackelford AG, McCall MM (2009) Trends and emerging technologies in extracorporeal life support: results of the 2006 ECLS survey. J Extra Corpor Technol 41:73\u201378","journal-title":"J Extra Corpor Technol"},{"key":"780_CR164","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","volume":"12","author":"E Sokolowska","year":"2016","unstructured":"Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (2016) The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol 12:897\u2013909","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"780_CR165","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpba.2017.03.010","volume":"140","author":"CD Sommers","year":"2017","unstructured":"Sommers CD, Ye H, Liu J, Linhardt RJ, Keire DA (2017) Heparin and homogeneous model heparin oligosaccharides form distinct complexes with protamine: light scattering and zeta potential analysis. J Pharm Biomed Anal 140:113\u2013121","journal-title":"J Pharm Biomed Anal"},{"key":"780_CR166","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1076029616643822","volume":"22","author":"K St Ange","year":"2016","unstructured":"St Ange K, Onishi A, Fu L, Sun X, Lin L, Mori D, Zhang F, Dordick JS, Fareed J, Hoppensteadt D, Jeske W, Linhardt RJ (2016) Analysis of heparins derived from bovine tissues and comparison to porcine intestinal heparins. Clin Appl Thromb Hemost 22:520\u2013527","journal-title":"Clin Appl Thromb Hemost"},{"key":"780_CR167","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark K, Massberg S (2021) Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 18:666\u2013682","journal-title":"Nat Rev Cardiol"},{"key":"780_CR168","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/s-0038-1661167","volume":"52","author":"Y Stirling","year":"1984","unstructured":"Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176\u2013182","journal-title":"Thromb Haemost"},{"key":"780_CR169","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1161\/CIRCULATIONAHA.108.830174","volume":"119","author":"WS Stoney","year":"2009","unstructured":"Stoney WS (2009) Evolution of cardiopulmonary bypass. Circulation 119:2844\u20132853","journal-title":"Circulation"},{"key":"780_CR170","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/ph17101362","volume":"17","author":"R Sultana","year":"2024","unstructured":"Sultana R, Kamihira M (2024) Multifaceted heparin: diverse applications beyond anticoagulant therapy. Pharmaceuticals (Basel) 17:1362","journal-title":"Pharmaceuticals (Basel)"},{"key":"780_CR171","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1440-1797.2010.01298.x","volume":"15","author":"M Suranyi","year":"2010","unstructured":"Suranyi M, Chow JS (2010) Review: anticoagulation for haemodialysis. Nephrology (Carlton) 15:386\u2013392","journal-title":"Nephrology (Carlton)"},{"key":"780_CR172","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nbt.3606","volume":"34","author":"AY Szajek","year":"2016","unstructured":"Szajek AY, Chess E, Johansen K, Gratzl G, Gray E, Keire D, Linhardt RJ, Liu J, Morris T, Mulloy B, Nasr M, Shriver Z, Torralba P, Viskov C, Williams R, Woodcock J, Workman W, Al-Hakim A (2016) The US regulatory and pharmacopeia response to the global heparin contamination crisis. Nat Biotechnol 34:625\u2013630","journal-title":"Nat Biotechnol"},{"key":"780_CR173","doi-asserted-by":"crossref","unstructured":"Testroote M, Stigter W, de Visser DC, Janzing H (2008) Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev:CD006681","DOI":"10.1002\/14651858.CD006681.pub2"},{"key":"780_CR174","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12288-023-01718-2","volume":"40","author":"V Thalappil","year":"2024","unstructured":"Thalappil V, Anand J, Keepanasseril A, Kar R (2024) Standardization of anti-Xa assay and its comparison with activated partial thromboplastin time for monitoring unfractionated heparin therapy. Indian J Hematol Blood Transfus 40:432\u2013436","journal-title":"Indian J Hematol Blood Transfus"},{"key":"780_CR175","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1161\/01.CIR.85.4.1380","volume":"85","author":"C Thery","year":"1992","unstructured":"Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP (1992) Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 85:1380\u20131389","journal-title":"Circulation"},{"key":"780_CR176","doi-asserted-by":"publisher","first-page":"35619","DOI":"10.1038\/srep35619","volume":"6","author":"AM Tovar","year":"2016","unstructured":"Tovar AM, Santos GR, Capille NV, Piquet AA, Glauser BF, Pereira MS, Vilanova E, Mourao PA (2016) Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs. Sci Rep 6:35619","journal-title":"Sci Rep"},{"key":"780_CR177","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1160\/TH08-02-0125","volume":"100","author":"J Trujillo-Santos","year":"2008","unstructured":"Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M, Riete Registry (2008) Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:435\u2013439","journal-title":"Thromb Haemost"},{"key":"780_CR178","unstructured":"USP_Heparin_Sodium. Heparin Sodium, United States Pharmacopeia, USP41-NF36"},{"key":"780_CR179","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1021\/acs.biomac.6b00699","volume":"17","author":"S Valimaki","year":"2016","unstructured":"Valimaki S, Khakalo A, Ora A, Johansson LS, Rojas OJ, Kostiainen MA (2016) Effect of PEG-PDMAEMA block copolymer architecture on polyelectrolyte complex formation with heparin. Biomacromolecules 17:2891\u20132900","journal-title":"Biomacromolecules"},{"key":"780_CR191","doi-asserted-by":"publisher","unstructured":"van Rein J.S., Biedermann F.J.M., van der Meer S.C., Cannegieter N., Wiersma H.W., Vermaas P.H., Reitsma M.J.H.A., Kruip W.M., Lijfering (2017) Major bleeding risks of different low\u2010molecular\u2010weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis Journal of Thrombosis and Haemostasis 15(7):1386\u20131391. https:\/\/doi.org\/10.1111\/jth.13715","DOI":"10.1111\/jth.13715"},{"key":"780_CR180","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmed.2019.00016","volume":"6","author":"E Vilanova","year":"2019","unstructured":"Vilanova E, Vairo BC, Smcg Oliveira BF, Glauser NV, Capille GRC, Santos AMF, Tovar MS, Pereira, Mourao PAS (2019) Heparins sourced from bovine and porcine mucosa gain exclusive monographs in the Brazilian pharmacopeia. Front Med (Lausanne) 6:16","journal-title":"Front Med (Lausanne)"},{"key":"780_CR181","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2710.2006.00769.x","volume":"31","author":"YY Wang","year":"2006","unstructured":"Wang YY, Po HL (2006) Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 31:513\u2013517","journal-title":"J Clin Pharm Ther"},{"key":"780_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119818","volume":"295","author":"P Wang","year":"2022","unstructured":"Wang P, Chi L, Zhang Z, Zhao H, Zhang F, Linhardt RJ (2022) Heparin: an old drug for new clinical applications. Carbohydr Polym 295:119818","journal-title":"Carbohydr Polym"},{"key":"780_CR183","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","volume":"141","author":"D Wardrop","year":"2008","unstructured":"Wardrop D, Keeling D (2008) The story of the discovery of heparin and warfarin. Br J Haematol 141:757\u2013763","journal-title":"Br J Haematol"},{"key":"780_CR184","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1007\/s00216-016-9940-y","volume":"408","author":"U Warttinger","year":"2016","unstructured":"Warttinger U, Giese C, Harenberg J, Holmer E, Kramer R (2016) A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma. Anal Bioanal Chem 408:8241\u20138251","journal-title":"Anal Bioanal Chem"},{"key":"780_CR185","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1160\/TH03-03-0152","volume":"90","author":"RH White","year":"2003","unstructured":"White RH, Zhou H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446\u2013455","journal-title":"Thromb Haemost"},{"key":"780_CR186","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","volume":"2","author":"DM Witt","year":"2018","unstructured":"Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2:3257\u20133291","journal-title":"Blood Adv"},{"key":"780_CR187","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood-2008-04-153288","volume":"112","author":"Z Xiao","year":"2008","unstructured":"Xiao Z, Visentin GP, Dayananda KM, Neelamegham S (2008) Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood 112:1091\u20131100","journal-title":"Blood"},{"key":"780_CR188","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/02676591241232513","volume":"40","author":"EB Yin","year":"2025","unstructured":"Yin EB, Bracey AW, Chatterjee S (2025) Thromboelastography versus thromboelastometry for unfractionated heparin monitoring in adult patients on extracorporeal membrane oxygenation. Perfusion 40:235\u2013242","journal-title":"Perfusion"},{"key":"780_CR189","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.thromres.2014.11.015","volume":"135","author":"S Zhang","year":"2015","unstructured":"Zhang S, Zhai Z, Yang Y, Zhu J, Gong J, Xie W, Kuang T, Wang C (2015) Long-term treatment with low-molecular-weight heparin prolonged the survival time for acute pulmonary embolism patients concurrent with malignancy: an observational analysis from a long-term follow-up study. Thromb Res 135:582\u2013587","journal-title":"Thromb Res"},{"key":"780_CR190","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1309\/Q4AE-BMCW-CQ7J-NUVT","volume":"113","author":"K Zmuda","year":"2000","unstructured":"Zmuda K, Neofotistos D, Ts'ao CH (2000) Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 113:725\u2013731","journal-title":"Am J Clin Pathol"}],"container-title":["Handbook of Experimental Pharmacology","Antithrombotic and Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2025_780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:02:30Z","timestamp":1777060950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2025_780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032228994","9783032229007"],"references-count":191,"URL":"https:\/\/doi.org\/10.1007\/164_2025_780","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"30 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}